CoChat

Remnant lipoproteins: are they equal to or more atherogenic than LDL?

Open access
Salinas, Carlos A. Aguilar, Chapman, M. John · 2020 · Current Opinion in Lipidology

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

Purpose of review: To critically appraise new insights into the biology of remnant lipoproteins and their putative role in the pathophysiology of atherosclerotic cardiovascular disease, and to compare the atherogenicity of remnant particles with that of low-density lipoproteins (LDL). Recent findings: New in-vivo stable isotope tracer studies of the kinetics of apoB48 and apoB100-containing lipoproteins in postprandial conditions have revealed that apoB48-containing very low-density lipoproteins (VLDL) accumulated markedly in hypertriglyceridemic patients. These intestinally-derived particles were cleared slowly, and represented up to 25% of circulating VLDL; as part of the remnant particle population, they may increase cardiovascular risk. Importantly, the PCSK9 inhibitor, evolocumab, was shown to reduce remnant levels (−29%) during the postprandial period in diabetic patients on statin therapy – an effect which may be additive to that of LDL-cholesterol reduction in conferring cardiovascular benefit. In recent Mendelian randomization studies, the effect of lowering triglyceride-rich lipoproteins or LDL-cholesterol translated to similar clinical benefit per unit of apoB. Finally, in randomized trials involving statin-treated patients with atherosclerotic cardiovascular disease, remnant cholesterol levels were associated with coronary atheroma progression independently of LDL-cholesterol. Summary: Overall, data from observational studies in large cohorts, Mendelian randomization studies, meta-regression analyses, and post-hoc analyses of randomized trials are consistent with the contention that remnants are highly atherogenic particles and contribute to the atherosclerotic burden in an equivalent manner to that of LDL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mol.0000000000000682

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Research works printed but not linked: 1

  1. Havel, 1997, Triglyceride-rich lipoprotein remnants, Handbook of Lipoprotein Testing, 451

Cited by

See all 93

Metadata

Authors
Salinas, C. A. A., & Chapman, M. J.
Affiliations
  • Unidad de Investigación en Enfermedades Metabólicas
  • Baker Heart and Diabetes Institute (AU)
Corresponding author
Chapman, M. John
Venue
Current Opinion in Lipidology
Published
2020-06
Volume
31
Issue
3
Pages
132-139
ISSN
  • 0957-9672 (ISSN-L)
  • 1473-6535
OpenAlex
W3019931280
Cited by
87
References
43
Citations by year
2026: 9 · 2025: 13 · 2024: 9 · 2023: 18 · 2022: 20 · 2021: 14 · 2020: 4
FWCI
3.17
Type
journal article
Language
en
Licence
other-oa
Locations
  • Current Opinion in Lipidology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
remnant lipoproteins, triglyceride-rich lipoproteins, atherogenicity, low-density lipoprotein, atherosclerotic cardiovascular disease, apolipoprotein B-48, apolipoprotein B-100, VLDL, postprandial lipemia, hypertriglyceridemia, PCSK9 inhibitors, evolocumab, remnant cholesterol, statin therapy, cardiovascular risk
MeSH terms
Proprotein Convertase 9, PCSK9 Inhibitors, Cardiovascular Diseases, Humans, Isotope Labeling, Lipoproteins, LDL, Lipoproteins, VLDL, Atherosclerosis, Apolipoprotein B-100, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Remnant lipoproteins: are they equal to or more atherogenic than LDL? https://app.cochat.ai/papers/10.1097/mol.0000000000000682
The paper
Salinas, C. A. A., & Chapman, M. J. (2020). Remnant lipoproteins: are they equal to or more atherogenic than LDL? Current Opinion in Lipidology. https://doi.org/10.1097/mol.0000000000000682

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.